Hormone receptor (HR)-positive / HER2-negative breast cancer is the most prevalent breast cancer subtype. Treatment decisions are influenced by disease stage, genetic test score, menopausal status, resectability, site of metastasis, and prior treatment received. The FDA approval of three CDK4/6 inhibitors in the metastatic setting (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) has changed physicians’ prescribing behavior and created new dynamics in treatment sequencing. Furthermore, the FDA approvals of two PARP inhibitors (AstraZeneca’s Lynparza and Pfizer’s Talzenna) for metastatic germline BRCA-mutation-positive, HER2-negative (including HR-positive) breast cancer patients, as well as one PI3K inhibitor (Novartis’s Piqray) for advancedPIK3CA-mutation-positive, HR-positive / HER2-negative breast cancer have provided additional treatment options for this patient subgroup.
Current Treatment: Physician insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.